GSK plc
GLAXF
$26.08
-$0.80-2.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 845.86M | 2.71B | 1.93B | 2.05B | 530.19M |
| Total Depreciation and Amortization | -832.56M | 995.12M | 1.55B | 1.04B | 257.41M |
| Total Amortization of Deferred Charges | 292.59M | -- | -- | -- | 270.22M |
| Total Other Non-Cash Items | 2.18B | -52.59M | -116.22M | 123.43M | 2.54B |
| Change in Net Operating Assets | 541.30M | -660.72M | -559.71M | -1.76B | -613.43M |
| Cash from Operations | 3.03B | 3.00B | 2.80B | 1.44B | 2.98B |
| Capital Expenditure | -762.07M | -419.35M | -341.97M | -261.97M | -696.68M |
| Sale of Property, Plant, and Equipment | 17.29M | 6.74M | 6.68M | 1.26M | 78.12M |
| Cash Acquisitions | -57.19M | -1.16B | -4.01M | -1.01B | -83.24M |
| Divestitures | 1.33M | 1.35M | -37.40M | -1.26M | -6.40M |
| Other Investing Activities | -440.22M | -493.52M | -458.19M | -167.51M | -724.85M |
| Cash from Investing | -1.24B | -2.06B | -834.89M | -1.44B | -1.43B |
| Total Debt Issued | 552.00M | -80.00M | 645.00M | 2.08B | 1.34B |
| Total Debt Repaid | -79.00M | -62.00M | -1.57B | -216.00M | -1.15B |
| Issuance of Common Stock | 1.00M | 0.00 | 2.00M | 12.00M | 0.00 |
| Repurchase of Common Stock | -252.00M | -317.00M | -561.00M | -247.00M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -859.16M | -876.46M | -876.30M | -770.80M | -783.76M |
| Other Financing Activities | -432.00M | -206.00M | -230.00M | -156.00M | -418.00M |
| Cash from Financing | -1.14B | -1.77B | -3.17B | 1.08B | -1.08B |
| Foreign Exchange rate Adjustments | -54.53M | 79.56M | -34.73M | -13.85M | 8.96M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 595.82M | -761.85M | -1.24B | 1.07B | 480.25M |